Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease

Arthritis and Rheumatism

Volumn 62, Issue 6, 2010, Pages 1755-1762

  Khosroshahi, Arezou ^a   Bloch, Donald B ^a   Deshpande, Vikram ^a   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AORTITIS; ARTICLE; AUTOIMMUNE PANCREATITIS; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED SYSTEMIC DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LACRIMAL GLAND DISEASE; LYMPHOCYTE DEPLETION; LYMPHOPLASMACYTIC AORTITIS; MALE; MIKULICZ DISEASE; NAUSEA; OBESITY; ORBIT PSEUDOTUMOR; PLASMA CELL; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS; SIALOADENITIS; SIDE EFFECT; SYSTEMIC DISEASE; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952919491     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27435     Document Type: Article

References (30)

1. Glassock RJ. Human idiopathic membranous nephropathy: a mystery solved? N Engl J Med 2009;361:81-83
2. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008;128:2859-2869
3. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009;68:1310-1315
4. Kamisawa T. IgG4-related sclerosing disease. Intern Med 2006;45: 125-126
5. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008;14:3948-3955
6. Stone JH, Caruso PA, Deshpande V. Case records of the Massachusetts General Hospital. Case 24-2009: a 26-year-old woman with painful swelling of the neck. N Engl J Med 2009;361:511-518
7. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-984 (Pubitemid 37455786)
8. Stone JH, Khosroshahi A, Hilgenberg A, Spooner A, Isselbacher EM, Stone JR. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 2009;60:3139-3145
9. Khosroshahi A, Stone JR, Pratt DS, Deshpande V, Stone JH. Painless jaundice with serial multi-organ dysfunction. Lancet 2009;373:1494.
10. Tabata T, Kamisawa T, Takuma K, Anjiki H, Egawa N, Kurata M, et al. Serum IgG4 concentrations and IgG4-related sclerosing disease. Clin Chim Acta 2009;408:25-28
11. Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007;102:2417-2425 (Pubitemid 47631797)
12. Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005;5: 234-238 (Pubitemid 40754743)
13. Matsushita M, Ikeura T, Fukui T, Uchida K, Okazaki K. Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy? [letter]. Am J Gastroenterol 2008;103:1834.
14. Okazaki K, Kawa S, Kamisawa T, Ito T, Inui K, Irie H, et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas 2009;38:849-866
15. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 2009;76:458-463
16. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009. E-pub ahead of print.
17. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-738 (Pubitemid 32204991)
18. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995;40:1561-1568
19. Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease [letter]. Am J Gastroenterol 2003;98:2811-2812 (Pubitemid 38020139)
20. Deshpande V, Chicano S, Finkelberg D, Selig MK, Mino-Kenudson M, Brugge WR, et al. Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol 2006;30: 1537-1545 (Pubitemid 44808790)
21. Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol 2006;41:1197-1205 (Pubitemid 46487210)
22. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-3590 (Pubitemid 39488683)
23. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006;54:3612-3622 (Pubitemid 44737173)
24. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008;10:R105.
25. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-3908
26. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response [published erratum appears in Ann Rheum Dis 2009;68:764]. Ann Rheum Dis 2008;67:330-334
27. Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007;45:1538-1546 (Pubitemid 46918338)
28. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-3259
29. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998;160:3555-3561 (Pubitemid 28164751)
30. Hirano K, Shiratori Y, Komatsu Y, Yamamoto N, Sasahira N, Toda N, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol 2003; 1:453-464